SJS Investment Consulting
RNA icon

SJS Investment Consulting’s Atrium Therapeutics RNA Stock Holding History

SJS Investment Consulting’s Portfolio RNA Stock Details RNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$605 Buy
73
+64
+711% +$755 ﹤0.01% 2691
2026
Q2 		$122 Buy
+9
New +$118 ﹤0.01% 2574

Other funds holding RNA

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Los Angeles Capital Management
Los Angeles Capital Management Los Angeles, California $29.2B AUM 33.64% 1-Year Est. Return
Arbiter Partners Capital Management
Arbiter Partners Capital Management New York $235M AUM 94.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Trium Capital
Trium Capital London, United Kingdom $79.4M AUM 36.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

SJS Investment Consulting's RNA Position: Q3 2026 in Review

SJS Investment Consulting increased its Atrium Therapeutics (RNA) stake by 711% in Q3 2026, buying an estimated $755 and bringing the position to 73 shares worth $605. The position accounts for ﹤0.01% of the portfolio, ranked #2691.

SJS Investment Consulting first reported a position in RNA in Q2 2026 and has held it in 2 quarters since. 52 funds tracked by Wall St. Rank hold RNA as of Q3 2026.

  • SJS Investment Consulting held 73 shares of Atrium Therapeutics worth $605 as of Q3 2026.
  • SJS Investment Consulting bought 64 Atrium Therapeutics shares in Q3 2026, an estimated $755.
  • Atrium Therapeutics made up ﹤0.01% of SJS Investment Consulting's portfolio in Q3 2026, its #2691 holding.
  • SJS Investment Consulting first reported a position in Atrium Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • 52 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q3 2026.

Based on SJS Investment Consulting's 13F filing for Q3 2026, filed 26 Oct 2026.